Primary Human Tumor Graft Services for Cancer Therapy Research

Sep 24 2012

The use of primary human tumors in xenograft studies has brought new hope to the field of oncology research. These patient-derived models may offer preferential preservation of original patient tumor characteristics compared to more traditional cell line-derived models, and thus have the potential to lead to predictive insights when developing cancer therapies.

Establishing tumor models from patient-derived tumor tissue (PDTT) at low passage is believed to conserve original tumor characteristics such as heterogeneous histology, clinical biomolecular signature, malignant phenotypes and genotypes, tumor architecture and tumor vasculature.

Charles River defines primary tumor tissue xenografts as patient-derived explants established as models at low passage numbers (less than ten passes removed from patient). They have not been grown in plastic or propagated as cell cultures. All Charles River patient-derived tumors are sourced from within the USA.

Models Currently Available for Study:

• 55 fully validated models across 12 histotypes, with several additional models in development

• Validation of models includes Standards of Care (SOC) sensitivity and resistance profiles

• Profiling includes protein expression, genomics, micro-tissue array and IHC and pathology

• Tumor samples are available for custom analysis

For more information about our primary tumor models, please contact us at 1.877.CRIVER.1 or askcharlesriver@crl.com.

Related Information

• Primary Human Tumor Grafts

• Human Tumor Xenograft in Nude Mice